Company intelligence / Profile preview
Oscient Pharmaceuticals Corporation
Waltham, Massachusetts, United States
- Ownership
- Private
- Employees
- ~205
- Development stage
- Other
01
Overview
Oscient developed and commercialized specialty pharmaceuticals including the antibiotic Factive® and the lipid-lowering agent ANTARA®. Its lead pipeline candidate was Ramoplanin for CDAD, which reached Phase III. The company filed for bankruptcy in July 2009 after financial difficulties. Key assets were sold off to other companies.[1][2]
- Therapeutic areas
- Men's HealthCardiovascularInfectious Diseases
- Modalities
- small molecules (e.g., antibiotics, cardiovascular drugs)[1][2][3]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Vicuron Pharmaceuticals/Pfizer Inc. – licensing agreement for Ramoplanin development rights.[1]
Beyond the preview
Go deeper on Oscient Pharmaceuticals Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oscient Pharmaceuticals Corporation.